Metanavigation:

Hier finden Sie den Zugang zur Notfallseite, Kontaktinformationen, Barrierefreiheits-Einstellungen, die Sprachwahl und die Suchfunktion.

Navigation öffnen

HOSFOS



Kurztitel: HOSFOS Registry

Untersuchte Krankheit: Morbus Fabry

Studienleitung: Dr. Sima Canaan-Kühl


Klinik, Institut: Medizinische Klinik m.S. Nephrologie und Internistische Intensivmedizin CCM

Patient/-in (krank)
Alter: 18 - 99
Geschlecht: Alle

Status: Teilnehmende gesucht
Stand: 10.12.2022

Zurück zur Übersicht



Sie befinden sich hier:

Studienbeschreibung

Titel

HOSFOS

Kurztitel

HOSFOS Registry

Allgemeinverständliche Kurzbeschreibung

A global, multinational, non-interventional, drug registry with longitudinal data collection

Wissenschaftliche Kurzbeschreibung

A global, multinational, non-interventional, drug registry with longitudinal data collection

Studienstart

16.09.2020

Untersuchte Krankheit, Gesundheitsproblem

ICD-Code
  • E75.2 - Sonstige Sphingolipidosen

Einschlusskriterien

Alter

18 - 99

Geschlecht

Alle

Weitere Einschlusskriterien

Fabry disease Population
Each patient must meet the following criteria to be enrolled in this registry:
1. Patients with a documented diagnosis of Fabry disease, which may include a genetic mutation analysis.
2. Patients who are untreated, currently treated with Replagal, or previously treated with any enzyme replacement therapy (ERT).
3. Signed and dated written informed consent from the patient or, for patients aged <18 years (or as per local regulation), parent and/or patient's legally authorized representative (LAR), and assent of the minor where applicable. If a patient is unable to read or if a legally acceptable representative is unable to read, an impartial witness should be present during the informed consent discussion and should sign and personally date the informed consent.

Ausschlusskriterien

Patients who meet any of the following criteria will be excluded from the Registry.
1. Patients who are receiving treatment with an ERT for Fabry disease other than Replagal.
2. Patients enrolled in a clinical study (except a Replagal open-label clinical study), are not eligible until they have completed or withdrawn from the clinical study.

Charakteristika

Studientyp

Nicht-interventionell

Studienphase

Nicht zutreffend

Zurück zur Übersicht